Skip to main content
Premium Trial:

Request an Annual Quote

Protagen Applying UNIarray Platform for Biogen's MS Drug Research

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – German biotech firm Protagen today announced it will be using its UNIarray platform to support Biogen Idec's efforts in finding therapies for multiple sclerosis.

Under the terms of the agreement, the UNIarray platform will be used to retrospectively analyze samples from a Biogen clinical trial in order to find predictive and response biomarkers in relapsing remitting MS. Protagen will also apply its expertise in autoantibody research to the alliance.

Financial and other terms of the deal were not disclosed.

"There is an acute need to discover possible response and non-response biomarkers in MS using genomic and proteomic levels," Peter Schulz-Knappe, CSO of Protagen, said in a statement. "Autoantibody signatures play an increasingly important role as a technology platform that could be used to identify patients for optimized treatment efficacy and to monitor disease progression."

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.